Specification of Drug Substances and Products

Development and Validation of Analytical Methods

Christopher M. Riley, Thomas W. Rosanske, George L. Reid (Herausgeber)

Buch | Softcover

694 Seiten

2020 | 2nd edition
Elsevier / The Lancet (Verlag)
9780081028247 (ISBN)

Infos

Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Second Edition, presents a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development, validation of analytical methods, and their application in practice. This thoroughly revised second edition covers topics not covered or not substantially covered in the first edition, including method development and validation in the clinical phase, method transfer, process analytical technology, analytical life cycle management, special challenges with generic drugs, genotoxic impurities, topical products, nasal sprays and inhalation products, and biotechnology products.

The book's authors have been carefully selected as former members of the ICH Expert Working Groups charged with developing the ICH guidelines, and/or subject-matter experts in the industry, academia and in government laboratories.

Autor

Dr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor’s degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms. Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee.

Inhalt

PART 1 INTRODUCTION
1. Introduction
2. General Principles and Regulatory Considerations: Specifications and Shelf Life Setting
3. General Principles and Regulatory Considerations: Method Development and Validation
4. Application of Quality by Design (QbD) to the Development and Validation of Analytical Methods
5. Analytical Methods in the Clinical Phase of Development
6. Method Transfer
7. Process Analytical Technology

PART 2 UNIVERSAL TESTS
8. Description and Identification
9. Assay and Impurities: Specifications
10. Assay and Impurities: Method Development and Life-Cycle Management
11. Assay and Impurities: Method Validation
12. Mutagenic Impurities
13. Residual Solvents
14. Inorganic Impurities (Elemental Impurities)

PART 3 SPECIFIC TESTS: DRUG SUBSTANCES
15. Solid State Characterization
16. Chiral Methods
17. Water Determination

PART 4 SPECIFIC TESTS DRUG PRODUCT
18. Drug Release: Oral Products
19. Topical Products
20. Extractables and Leachables

PART 5 BIOTECHNOLOGY PRODUCTS
21. Regulatory Requirements for Setting Drug Substance and Drug Product Specifications 
22. Validation of Analytical Methods for Biotechnology Products

PART 6 PHARMACOPEIAL METHODS
23. Pharmacopeial Methods and Test (Updated)

PART 7 BIOLOGICAL FLUIDS
24. Biological Fluids

Produkt-Details

• Erscheinungsdatum: 02.07.2020
• Verlagsort: London
• Sprache: englisch
• Maße: 191 x 235 mm
• Gewicht: 1540 g
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Naturwissenschaften ► Chemie ► Analytische Chemie
• Themenwelt: Naturwissenschaften ► Chemie ► Organische Chemie
• ISBN-13: 9780081028247 / 9780081028247
• Zustand: Neuware